# CLARITY-PanTumour01 (NCT06219941)

> AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

No report yet. It can be ordered.

- Drugs tested: sonesitatug vedotin (AZD0901)
- Indication: claudin 18.2-expressing advanced solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06219941
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: AstraZeneca
- Conditions: Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarcinoma
- Interventions: AZD0901; 5-Fluorouracil; Leucovorin; l-leucovorin; Irinotecan; Nanoliposomal Irinotecan; Gemcitabine
- Enrollment: 226
- Primary outcome: Incidence of adverse events (AEs), serious AEs (SAEs). Changes from baseline in clinical laboratory parameters, vital signs, ECGs and physical examination. Rate of AEs leading to discontinuation of AZD0901, Occurrence of DLTs.
- Primary outcome: Objective Response Rate (ORR).

## Indexed commentary on CLARITY-PanTumour01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 2
- Podcasts: 2
- X threads: 1

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=clarity-pantumour01-nct06219941